Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 4/2018

01-12-2018

The protective effect of myo-inositol on human thyrocytes

Authors: Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Claudia Caruso, Salvatore Benvenga, Poupak Fallahi, Alessandro Antonelli

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2018

Login to get access

Abstract

Patients affected by autoimmune thyroiditis reached positive effects on indices of thyroid autoimmunity and/or thyroidal function, after following a treatment with selenomethionine (Se) alone, or Se in combination with Myo-inositol (Myo-Ins). Our purpose was to investigate if Myo-Ins alone, or a combination of Se + Myo-Ins, is effective in protecting thyroid cells from the effects given by cytokines, or hydrogen peroxide (H2O2). We assessed the interferon (IFN)-γ-inducible protein 10 (IP-10/CXCL10) secretion by stimulating primary thyrocytes (obtained from Hashimoto’s thyroiditis or from control patients) with cytokines in presence/absence of H2O2. Our results confirm: 1) the toxic effect of H2O2 in primary thyrocytes that leads to an increase of the apoptosis, to a decrease of the proliferation, and to a slight reduction of cytokines-induced CXCL10 secretion; 2) the secretion of CXCL10 chemokine induced by IFN-γ + tumor necrosis factor alpha (TNF)-α has been decreased by Myo + Ins, both in presence or absence of H2O2; 3) no effect has been shown by the treatment with Se. Therefore, a protective effect of Myo-Ins on thyroid cells has been suggested by our data, which exact mechanisms are at the basis of this effect need to be furtherly investigated.
Literature
1.
Garmendia Madiaraga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99:923–31.CrossRef
2.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489–99.
3.
Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in north-eastern Sicily and Calabria (southern Italy) based on a 31-year experience. Thyroid. 2008;18:429–41.CrossRefPubMed
4.
Latina A, Gullo D, Trimarchi F, Benvenga S. Hashimoto's thyroiditis: similar and dissimilar characteristics in neighboring areas. Possible implications for the epidemiology of thyroid cancer. PLoS One. 2013;8:e55450.CrossRefPubMedPubMedCentral
5.
Rizzo M, Rossi RT, Bonaffini O, Scisca C, Altavilla G, Calbo L, et al. Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris). 2010;71:525–34.CrossRef
6.
Baser H, Can U, Baser S, Yerlikaya FH, Aslan U, Hidayetoglu BT. Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. Endocrine. 2015;48:916–23.CrossRefPubMed
7.
Rostami R, Aghasi MR, Mohammadi A, Nourooz-Zadeh J. Enhanced oxidative stress in Hashimoto's thyroiditis: inter-relationships to biomarkers of thyroid function. Clin Biochem. 2013;46:308–12.CrossRefPubMed
8.
Ademoğlu E, Ozbey N, Erbil Y, Tanrikulu S, Barbaros U, Yanik BT, et al. Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. Eur J Intern Med. 2006;17:545–50.
9.
Tang XL, Liu XJ, Sun WM, Zhao J, Zheng RL. Oxidative stress in Graves' disease patients and antioxidant protection against lymphocytes DNA damage in vitro. Pharmazie. 2005;60:696–700.PubMed
10.
Song Y, Driessens N, Costa M, De Deken X, Detours V, Corvilain B, et al. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab. 2007;92:3764–73.CrossRefPubMed
11.
Riou C, Remy C, Rabilloud R, Rousset B, Fonlupt P. H2O2 induces apoptosis of pig thyrocytes in culture. J Endocrinol. 1998;156:315–22.CrossRefPubMed
12.
Granger DN, Vowinkel T, Petnehazy T. Modulation of the inflammatory response in cardiovascular disease. Hypertension. 2004;43:924–31.CrossRefPubMed
13.
Kiyoshima T, Enoki N, Kobayashi I, Sakai T, Nagata K, Wada H, et al. Oxidative stress caused by a low concentration of hydrogen peroxide induces senescence-like changes in mouse gingival fibroblasts. Int J Mol Med. 2012;30:1007–12.CrossRefPubMedPubMedCentral
14.
Kimura S, Yonemura T, Kaya H. Increased oxidative product formation by peripheral blood polymorphonuclear leukocytes in human periodontal diseases. J Periodontal Res. 1993;28:197–203.CrossRefPubMed
15.
Chiaradia E, Gaiti A, Scaringi L, Cornacchione P, Marconi P, Avellini L. Antioxidant systems and lymphocyte proliferation in the horse, sheep and dog. Vet Res. 2002;33:661–8.CrossRefPubMed
16.
17.
Zhu D, Tan KS, Zhang X, Sun AY, Sun GY, Lee JC. Hydrogen peroxide alters membrane and cytoskeleton properties and increases intercellular connections in astrocytes. J Cell Sci. 2005;118:3695–703.CrossRefPubMed
18.
Nakayama N, Yamaguchi S, Sasaki Y, Chikuma T. Hydrogen peroxide-induced oxidative stress activates proteasomal trypsin-like activity in human U373 glioma cells. J Mol Neurosci. 2016;58:297–305.CrossRefPubMed
19.
Janero DR, Hreniuk D, Sharif HM. Hydrogen peroxide-induced oxidative stress to the mammalian heart-muscle cell (cardiomyocyte): lethal peroxidative membrane injury. J Cell Physiol. 1991;149:347–64.CrossRefPubMed
20.
Benhamou PY, Moriscot C, Richard MJ, Beatrix O, Badet L, Pattou F, et al. Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets. Diabetologia. 1998;41:1093–100.
21.
Maechler P, Jornot L, Wollheim CB. Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. J Biol Chem. 1999;274:27905–13.CrossRefPubMed
22.
Pierre N, Barbé C, Gilson H, Deldicque L, Raymackers JM, Francaux M. Activation of ER stress by hydrogen peroxide in C2C12 myotubes. Biochem Biophys Res Commun. 2014;450:459–63.CrossRefPubMed
23.
24.
Choo KB, Tai L, Hymavathee KS, Wong CY, Nguyen PN, Huang CJ, et al. Oxidative stress-induced premature senescence in Wharton's jelly-derived mesenchymal stem cells. Int J Med Sci. 2014;11:1201–7.CrossRefPubMedPubMedCentral
25.
Do GY, Kim JW, Chae SK, Ahn JH, Park HJ, Park JY, et al. Antioxidant effect of edaravone on the development of preimplantation porcine embryos against hydrogen peroxide-induced oxidative stress. J Embryo Transfer. 2016;30:289–98.CrossRef
26.
Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2007;14:398–409.CrossRefPubMed
27.
Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–80.CrossRefPubMed
28.
29.
Luster AD, Jhanwar SC, Chaganti RS, Kersey JH, Ravetch JV. Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells. Proc Natl Acad Sci U S A. 1987;84:2868–71.CrossRefPubMedPubMedCentral
30.
Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med. 1995;182:1301–14.CrossRefPubMed
31.
32.
Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–80.CrossRefPubMed
33.
Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev. 2014;25:57–65.CrossRefPubMed
34.
Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, et al. Interferon-alpha, −beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine. 2010;50:260–7.
35.
Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab. 2010;95:E413–20.
36.
Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2011;96:1859–63.CrossRefPubMed
37.
Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol. 2009;27:22–7.
38.
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine. 2008;42:137–43.
39.
Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine. 2011;55:288–93.
40.
41.
Gärtner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87:1687–91.CrossRefPubMed
42.
Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007;92:1263–8.CrossRefPubMed
43.
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W, European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011;364:1920–31.
44.
Nordio M, Pajalich R. Combined treatment with Myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis. J Thyroid Res. 2013;2013:424163.CrossRefPubMedPubMedCentral
45.
Benvenga S, Amato A, Calvani M, Trimarchi F. Effects of carnitine on thyroid hormone action. Ann N Y Acad Sci. 2004;1033:158–67.CrossRefPubMed
46.
Chee R, Agah R, Vita R, Benvenga S. L-carnitine treatment in a seriously ill cancer patient with severe hyperthyroidism. Hormones (Athens). 2014;13:407–12.
47.
Jiang WD, Hu K, Liu Y, Jiang J, Wu P, Zhao J, et al. Dietary myo-inositol modulates immunity through antioxidant activity and the Nrf2 and E2F4/cyclin signalling factors in the head kidney and spleen following infection of juvenile fish with Aeromonas hydrophila. Fish Shellfish Immunol. 2016;49:374–86.
48.
Agarwal A, Durairajanayagam D, du Plessis SS. Utility of antioxidants during assisted reproductive techniques: an evidence based review. Reprod Biol Endocrinol. 2014;12:112.CrossRefPubMedPubMedCentral
49.
50.
World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Bulletin of the World Health Organization. 2001:79.
51.
Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94:1803–9.
52.
Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2006;91:614–20.
53.
Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503–8.
54.
Ferrari SM, Fallahi P, La Motta C, Bocci G, Corrado A, Materazzi G, et al. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. Surgery. 2014;156:1167–76.CrossRefPubMed
55.
Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014;99:E572–81.CrossRefPubMed
56.
Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96:E288–96.CrossRefPubMed
57.
Antonelli A, Ferrari SM, Frascerra S, Corrado A, Pupilli C, Bernini G, et al. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res. 2011;317:1527–33.
58.
Benvenga S, Antonelli A. Inositol(s) in thyroid function, growth and autoimmunity. Rev Endocr Metab Disord. 2016;17:471–84.CrossRefPubMed
59.
Ohye H, Sugawara M. Dual oxidase, hydrogen peroxide and thyroid diseases. Exp Biol Med (Maywood). 2010;235:424–33.CrossRef
60.
Grasberger H, Van Sande J, Hag-Dahood Mahameed A, Tenenbaum-Rakover Y, Refetoff S. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab. 2007;92:2816–20.CrossRefPubMed
61.
62.
Kashiwada M, Lu P, Rothman PB. PIP3 pathway in regulatory T cells and autoimmunity. Immunol Res. 2007;39:194–224.CrossRefPubMed
63.
Martino E, Macchia E, Aghini-Lombardi F, Antonelli A, Lenziardi M, Concetti R, et al. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis (AIIT)? Clin Endocrinol. 1986;24:627–33.CrossRef
64.
Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid. 2007;17:609–12.
65.
Zhu L, Bai X, Teng WP, Shan ZY, Wang WW, Fan CL, et al. Effects of selenium supplementation on antibodies of autoimmune thyroiditis. Zhonghua Yi Xue Za Zhi. 2012;92:2256–60.
66.
Nordio M, Basciani S. Myo-inositol plus selenium supplementation restores euthyroid state in Hashimoto's patients with subclinical hypothyroidism. Eur Rev Med Pharmacol Sci. 2017;21(Suppl2):51–9.PubMed
67.
Ferrari SM, Fallahi P, Di Bari F, Vita R, Benvenga S, Antonelli A. Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis. Eur Rev Med Pharmacol Sci. 2017;21(Suppl 2):36–42.PubMed
68.
Nordio M, Basciani S. Treatment with Myo-inositol and selenium ensures Euthyroidism in patients with autoimmune thyroiditis. Int J Endocrinol. 2017;2017:2549491.CrossRefPubMedPubMedCentral
69.
Esposito D, Rotondi M, Accardo G, Vallone G, Conzo G, Docimo G, et al. Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. J Endocrinol Investig. 2017;40:83–9.
70.
Benvenga S, Vicchio T, Di Bari F, Vita R, Fallahi P, Ferrari SM, et al. Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto's thyroiditis: preliminary in vitro studies. Eur Rev Med Pharmacol Sci. 2017;21(Suppl 2):89–101.PubMed
Metadata
Title
The protective effect of myo-inositol on human thyrocytes
Authors
Silvia Martina Ferrari
Giusy Elia
Francesca Ragusa
Sabrina Rosaria Paparo
Claudia Caruso
Salvatore Benvenga
Poupak Fallahi
Alessandro Antonelli
Publication date
01-12-2018
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2018
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-018-9476-x

Other articles of this Issue 4/2018

Reviews in Endocrine and Metabolic Disorders 4/2018 Go to the issue

ReviewPaper

Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions

ReviewPaper

Thyroid diseases and skin autoimmunity

ReviewPaper

Endocrine disorders associated with hepatitis C virus chronic infection

ReviewPaper

Thyroid disorders induced by checkpoint inhibitors

EditorialNotes

Immunoendocrinology: When (neuro)endocrinology and immunology meet

ReviewPaper

Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits